Xtl Biopharmaceuticals annual ebitda
2015
2016
2017
2020
2021
2022
2023
2024
2025
Xtl Biopharmaceuticals EBITDA Growth & History (XTLB)
Xtl Biopharmaceuticals's calculated EBITDA was −$752,000 for fiscal 2025.
View full Xtl Biopharmaceuticals company overviewXtl Biopharmaceuticals annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$752,000 | $1.1M | — |
| 2024 | 2024-12-31 | −$1.8M | −$26,000 | — |
| 2023 | 2023-12-31 | −$1.8M | −$903,000 | — |
| 2022 | 2022-12-31 | −$879,000 | $151,000 | — |
| 2021 | 2021-12-31 | −$1.0M | −$83,000 | — |
| 2020 | 2020-12-31 | −$947,000 | — | — |
| 2017 | 2017-12-31 | −$1.2M | $1.3M | — |
| 2016 | 2016-12-31 | −$2.6M | $1.0M | — |
| 2015 | 2015-12-31 | −$3.6M | — | — |
Xtl Biopharmaceuticals quarterly ebitda
Q4.24
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q4 2024 | 2024-12-31 | −$479,000 | — | — |
Xtl Biopharmaceuticals ebitda trends
Over the last five fiscal years, Xtl Biopharmaceuticals's ebitda increased from −$947,000 to −$752,000, a change of $195,000. The latest reported quarter, Q4 2024, shows −$479,000.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xtl Biopharmaceuticals source filings ↗